Sartar Therapeutics

Executive Summary

Sartar Therapeutics is a Finnish biotechnology company pioneering a novel class of cancer therapies based on phosphodiesterase 3A (PDE3A) as a first-in-class molecular glue target. Founded in 2018, the company is developing oral small molecules for gastrointestinal stromal tumors (GIST) and other soft tissue sarcomas—rare cancers with high unmet need. Its lead candidate leverages a breakthrough mechanism that selectively degrades PDE3A, triggering tumor cell death. Preclinical data suggest potent activity in GIST models resistant to standard therapies, positioning Sartar for a potential paradigm shift in sarcoma treatment. The company is currently in the pre-clinical stage, advancing toward Investigational New Drug (IND)-enabling studies. With a focused pipeline and a novel target validated by early academic studies, Sartar represents a high-risk, high-reward opportunity in precision oncology.

Upcoming Catalysts (preview)

• Q3 2026IND Submission for Lead Candidate (PDE3A Degrader in GIST)60% success
• Q2 2026Publication of Preclinical In Vivo Efficacy Data in Peer-Reviewed Journal80% success
• H2 2026Potential Partnership or Licensing Deal for PDE3A Platform40% success